Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Equities researchers at Cantor Fitzgerald raised their FY2017 EPS estimates for shares of Sunesis Pharmaceuticals in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein now anticipates that the biopharmaceutical company will post earnings of ($2.07) per share for the year, up from their previous estimate of ($2.08). Cantor Fitzgerald currently has a “Hold” rating on the stock.
Separately, Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $4.50 price objective for the company in a report on Thursday, January 19th.
COPYRIGHT VIOLATION WARNING: “Sunesis Pharmaceuticals, Inc. (SNSS) to Post FY2017 Earnings of ($2.07) Per Share, Cantor Fitzgerald Forecasts” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/04/21/fy2017-earnings-estimate-for-sunesis-pharmaceuticals-inc-snss-issued-by-cantor-fitzgerald-updated-updated.html.
Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 1.85% during mid-day trading on Thursday, reaching $3.71. 47,423 shares of the company’s stock traded hands. Sunesis Pharmaceuticals has a 12-month low of $2.63 and a 12-month high of $6.30. The stock’s market capitalization is $77.63 million. The stock has a 50-day moving average price of $4.05 and a 200-day moving average price of $4.02.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.01. The business earned $0.68 million during the quarter, compared to the consensus estimate of $0.60 million. Sunesis Pharmaceuticals had a negative return on equity of 806.43% and a negative net margin of 1,623.12%. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.91) earnings per share.
A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 16,000 shares in the last quarter. Vivo Capital LLC acquired a new stake in Sunesis Pharmaceuticals during the fourth quarter valued at approximately $1,810,000. Boxer Capital LLC acquired a new stake in Sunesis Pharmaceuticals during the fourth quarter valued at approximately $1,901,000. Baker BROS. Advisors LP acquired a new stake in Sunesis Pharmaceuticals during the third quarter valued at approximately $3,241,000. Finally, Great Point Partners LLC acquired a new stake in Sunesis Pharmaceuticals during the third quarter valued at approximately $4,648,000. Institutional investors own 34.30% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Sunesis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sunesis Pharmaceuticals Inc. and related companies.